We are live on ! Find out more
HS

HighVista Strategies Portfolio holdings

AUM $362M
1-Year Est. Return 230.96%
This Fund
S&P 500
This Quarter Est. Return
+69.32%
1 Year Est. Return
+230.96%
3 Year Est. Return
+518.4%
5 Year Est. Return
+644.94%
10 Year Est. Return
+2,223.31%
AUM
$408M
AUM Growth
+$136M
Cap. Flow
+$68.1M
Cap. Flow %
16.68%
Top 10 Hldgs %
29.1%
Holding
175
New
29
Increased
78
Reduced
38
Closed
27

Top Buys

Rank Stock Value
1
ABVX
Abivax
ABVX
+$8.17M
2
AGIO icon
Agios Pharmaceuticals
AGIO
+$4.71M
3
INSM icon
Insmed
INSM
+$4.7M
4
CDTX
Cidara Therapeutics
CDTX
+$4.52M
5
ACLX
Arcellx
ACLX
+$4.35M

Top Sells

Rank Stock Value
1
ANSS
Ansys
ANSS
+$6.01M
2
JNPR
Juniper Networks
JNPR
+$4.58M
3
HES
Hess
HES
+$4M
4
AMED
Amedisys
AMED
+$3.86M
5
WDC icon
Western Digital
WDC
+$2.97M

Sector Composition

Rank Sector Weight
1 Healthcare 59%
2 Technology 12.01%
3 Industrials 6.97%
4 Financials 4.64%
5 Consumer Discretionary 3.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DBC icon
1
Invesco DB Commodity Index Tracking Fund
DBC
$1.69B
$32.4M 7.93%
1,436,136
– –
ABVX
2
Abivax
ABVX
$10.4B
$15.7M 3.84%
184,468
+133,312
+261% +$8.17M
MRUS
3
DELISTED
Merus
MRUS
$12.6M 3.08%
133,321
+43,559
+49% +$2.84M
VRDN icon
4
Viridian Therapeutics
VRDN
$2.2B
$10.1M 2.48%
469,335
-15,224
-3% -$275K
RVMD icon
5
Revolution Medicines
RVMD
$38.5B
$8.19M 2.01%
175,448
+107,400
+158% +$4.21M
PTGX icon
6
Protagonist Therapeutics
PTGX
$8.55B
$8.08M 1.98%
121,682
+63,831
+110% +$3.63M
NUVL
7
DELISTED
Nuvalent
NUVL
$8.07M 1.98%
93,294
+42,834
+85% +$3.39M
MLYS icon
8
Mineralys Therapeutics
MLYS
$2.32B
$7.96M 1.95%
209,829
+59,691
+40% +$1.29M
ACLX
9
DELISTED
Arcellx
ACLX
$7.9M 1.94%
96,177
+60,463
+169% +$4.35M
AGIO icon
10
Agios Pharmaceuticals
AGIO
$2.08B
$7.84M 1.92%
195,298
+125,171
+178% +$4.71M
CYTK icon
11
Cytokinetics
CYTK
$10.6B
$7.31M 1.79%
132,930
+64,278
+94% +$2.65M
INSM icon
12
Insmed
INSM
$22.4B
$7.19M 1.76%
49,949
+38,354
+331% +$4.7M
CDTX
13
DELISTED
Cidara Therapeutics
CDTX
$6.79M 1.66%
+70,904
New +$4.52M
COGT icon
14
Cogent Biosciences
COGT
$6.76B
$6.64M 1.63%
462,405
+179,219
+63% +$2.12M
GPCR icon
15
Structure Therapeutics
GPCR
$3.37B
$6.61M 1.62%
236,236
+149,615
+173% +$2.98M
AMZN icon
16
Amazon
AMZN
$2.44T
$5.8M 1.42%
26,393
+7,500
+40% +$1.7M
SNDK
17
Sandisk
SNDK
$150B
$5.32M 1.31%
47,451
+7,851
+20% +$458K
ELVN icon
18
Enliven Therapeutics
ELVN
$3.78B
$5.3M 1.3%
259,135
+117,619
+83% +$2.37M
AKRO
19
DELISTED
Akero Therapeutics
AKRO
$5.23M 1.28%
110,079
+50,086
+83% +$2.43M
PRAX icon
20
Praxis Precision Medicines
PRAX
$8.11B
$5.04M 1.23%
95,002
+27,714
+41% +$1.34M
MSFT icon
21
Microsoft
MSFT
$2.9T
$4.9M 1.2%
9,458
-800
-8% -$408K
OLMA icon
22
Olema Pharmaceuticals
OLMA
$977M
$4.28M 1.05%
437,179
+158,749
+57% +$953K
BBIO icon
23
BridgeBio Pharma
BBIO
$16.4B
$4.26M 1.04%
81,959
+14,460
+21% +$705K
APGE icon
24
Apogee Therapeutics
APGE
$10.1B
$4.26M 1.04%
107,107
+62,055
+138% +$2.37M
IMVT icon
25
Immunovant
IMVT
$7.93B
$4.08M 1%
253,127
+70,319
+38% +$1.14M
1
2 3 4 5

Similar funds

SIAG
Safeguard Investment Advisory Group Corona, California $362M AUM 20.96% 1-Year Est. Return
MS
Millington Securities Red Bank, New Jersey $362M AUM
WI
WBI Investments Red Bank, New Jersey $362M AUM 23.75% 1-Year Est. Return
BHBT
Burke & Herbert Bank & Trust Alexandria, Virginia $362M AUM 20.5% 1-Year Est. Return
WTFG
Wood Tarver Financial Group Boise, Idaho $362M AUM 14.75% 1-Year Est. Return
RC
Reik & Co New York $363M AUM 3.03% 1-Year Est. Return
VIA
Virtus Investment Advisers Hartford, Connecticut $363M AUM 34.89% 1-Year Est. Return
A6
Anchor @ 65 Singapore $362M AUM 20.02% 1-Year Est. Return

HighVista Strategies's Q3 2025 Portfolio in Review

As of Q3 2025, HighVista Strategies held 175 positions worth $408M, up 50% from $272M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

HighVista Strategies deployed $68.1M of net new capital in Q3 2025, opening 29 new positions and adding to 78 existing holdings. Its largest new stake was Cidara Therapeutics: 70,904 shares worth $6.79M.

By sector, the portfolio is most concentrated in Healthcare at 59% of assets, up from 38% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Western Digital, an estimated $2.97M trimmed.

  • HighVista Strategies's largest Q3 2025 buy was Cidara Therapeutics: 70,904 shares worth $6.79M.
  • HighVista Strategies added most to Abivax in Q3 2025, an estimated $8.17M increase.
  • HighVista Strategies's biggest Q3 2025 reduction was Western Digital, cutting an estimated $2.97M.
  • HighVista Strategies fully exited Ansys in Q3 2025, selling an estimated $6.01M.
  • HighVista Strategies's ten largest holdings make up 29% of its $408M portfolio in Q3 2025.
  • HighVista Strategies opened 29 new positions and closed 27 in Q3 2025.
  • HighVista Strategies's portfolio value rose 50% quarter-over-quarter to $408M.

Based on HighVista Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.